We're over the moon to share the news of Samphire Neuroscience' $2.3m Seed round, where we were delighted to double down on our initial investment. For the millions of women around the world who face a monthly battle with debilitating menstrual pain and other symptoms (brain fog, fatigue, mood variability), Samphire may soon provide welcome relief. As in reported in Techstars, Samphire Neuroscience has developed a head-mounted therapeutic wearable that applies a non-invasive, low electrical current type of brain stimulation, called tDCS (transcranial direct current stimulation). The wearable targets regions of the brain associated with pain perception and mood regulation to, essentially, reduce sensitivity and block pain signals — applying (non-pharmaceutical) neuromodulation as a targeted treatment for period pain and PMS. Congratulations to Emilė R. and Alex Cook on your big day! #femtech
🧠
Sign 👏 me 👏 up 👏 congratulations to Samphire Neuroscience and AfterWork Ventures
Congrats, Alex and Emilé.
Congrats team!! 💕
Congrats team!
Amazing job team!
Amazing work!
Congrats!
CEO at Samphire Neuroscience | Neuro at Oxford & Harvard | Forbes 30 under 30 2024
8moThank you AfterWork Ventures for giving us the first nudge of support 🥹